All In Biotech

Drug Trial Radar · NCT00269412

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 525 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

525

Planned (sponsor's estimate)

Start

Dec 2005

Primary completion

Aug 2007

Study completion Sep 2008

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days. These four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. A fifth group of subjects will receive rifaximin 550 mg BID for a period of 28 days. Subjects who successfully respond to treatment at the end of the 28-day Treatment Phase will be followed in a Post-treatment Phase that includes study visits during Weeks 6, 8, 12 and 16. Subjects who relapse during the Post-treatment Phase will be discontinued from the study.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • RifaximinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Premeire Pharmaceutical Research

    Tempe, Arizona

  • Advanced Clinical Research Institute

    Anaheim, California

  • Lovelace Scientific Resources

    Irvine, California

  • West Gastroenterology Medical Group

    Los Angeles, California

  • Beverly Hills Gastroenterology

    Los Angeles, California

  • Medical Associates Research Group

    San Diego, California

  • Gastroenterology Associates of Fairfield County

    Bridgeport, Connecticut

  • Connecticut Gastroenterology Institute

    Bristol, Connecticut

  • Litchfield County Gastroenterology Associates, LLC

    Torrington, Connecticut

  • Clinical Research of West Florida

    Clearwater, Florida

  • University Clinical Research

    DeLand, Florida

  • Research Consultants Group

    Hialeah, Florida

  • Borland-Groover Clinic

    Jacksonville, Florida

  • Miami Research Associates

    Miami, Florida

  • Advanced Gastroenterology Associates

    Palm Harbor, Florida

  • Shafran Gastroenterology

    Winter Park, Florida

  • Florida Medical Clinic

    Zephyrhills, Florida

  • Rockford Gastroenterology

    Rockford, Illinois

  • Community Clinical Research Center

    Anderson, Indiana

  • Indianapolis Gastroenterology Research Foundation

    Indianapolis, Indiana

  • Gastrointestinal Clinic of Quad Citites

    Davenport, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Digestive Disorders Associates

    Annapolis, Maryland

  • Chevy Chase Clinical Research

    Chevy Chase, Maryland

  • Washington County Hospital

    Hagerstown, Maryland

  • Maryland Clinical Trials

    Severna Park, Maryland

  • Capital Gastroenterology Consultants, PA

    Silver Springs, Maryland

  • Coastal Research Associates

    Braintree, Massachusetts

  • Henry Ford Hospital

    Chesterfield, Michigan

  • Gastrointestinal Associates, PA

    Jackson, Mississippi

  • Digestive Health Specialists, PA

    Tupelo, Mississippi

  • Gastroenterology and Hepatology

    Kansas City, Missouri

  • Center for Digestive & Liver Diseases, Inc.

    Mexico, Missouri

  • Specialist in Gastroenterology

    St Louis, Missouri

  • Gastroenterology Specialities

    Lincoln, Nebraska

  • Long Island Clinical Research

    Great Neck, New York

  • New York Center for Clinical Research

    Lake Success, New York

  • Asheville Gastroenterology Associates

    Asheville, North Carolina

  • University of North Carolina

    Chapel Hill, North Carolina

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.